MA69209B1 - Composition solide comprenant des antagonistes solubilisés de récepteur b2 de la bradykinine - Google Patents
Composition solide comprenant des antagonistes solubilisés de récepteur b2 de la bradykinineInfo
- Publication number
- MA69209B1 MA69209B1 MA69209A MA69209A MA69209B1 MA 69209 B1 MA69209 B1 MA 69209B1 MA 69209 A MA69209 A MA 69209A MA 69209 A MA69209 A MA 69209A MA 69209 B1 MA69209 B1 MA 69209B1
- Authority
- MA
- Morocco
- Prior art keywords
- bradykinin
- methyl
- solubilized
- solid dispersions
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164462 | 2022-03-25 | ||
| EP23715487.7A EP4499038B1 (en) | 2022-03-25 | 2023-03-27 | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
| PCT/EP2023/057791 WO2023180575A1 (en) | 2022-03-25 | 2023-03-27 | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA69209B1 true MA69209B1 (fr) | 2026-03-31 |
Family
ID=80952146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA69209A MA69209B1 (fr) | 2022-03-25 | 2023-03-27 | Composition solide comprenant des antagonistes solubilisés de récepteur b2 de la bradykinine |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250228781A1 (enExample) |
| EP (1) | EP4499038B1 (enExample) |
| JP (1) | JP2025512818A (enExample) |
| KR (1) | KR20240161689A (enExample) |
| CN (1) | CN119136785A (enExample) |
| AU (1) | AU2023241243A1 (enExample) |
| CA (1) | CA3250835A1 (enExample) |
| CO (1) | CO2024012879A2 (enExample) |
| ES (1) | ES3062067T3 (enExample) |
| HR (1) | HRP20260166T1 (enExample) |
| IL (1) | IL315699A (enExample) |
| MA (1) | MA69209B1 (enExample) |
| MX (1) | MX2024011703A (enExample) |
| PL (1) | PL4499038T3 (enExample) |
| WO (1) | WO2023180575A1 (enExample) |
| ZA (1) | ZA202408058B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102824038B1 (ko) | 2025-01-20 | 2025-06-23 | 송재혁 | 차량 종합 검사 시스템 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物 |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| EP1123288A1 (en) | 1998-10-21 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| SMT202200154T1 (it) | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Nuovi antagonisti del recettore della bradichinina b2 |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| CA3198246A1 (en) * | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
-
2023
- 2023-03-27 HR HRP20260166TT patent/HRP20260166T1/hr unknown
- 2023-03-27 AU AU2023241243A patent/AU2023241243A1/en active Pending
- 2023-03-27 CA CA3250835A patent/CA3250835A1/en active Pending
- 2023-03-27 PL PL23715487.7T patent/PL4499038T3/pl unknown
- 2023-03-27 US US18/850,679 patent/US20250228781A1/en active Pending
- 2023-03-27 EP EP23715487.7A patent/EP4499038B1/en active Active
- 2023-03-27 WO PCT/EP2023/057791 patent/WO2023180575A1/en not_active Ceased
- 2023-03-27 ES ES23715487T patent/ES3062067T3/es active Active
- 2023-03-27 IL IL315699A patent/IL315699A/en unknown
- 2023-03-27 KR KR1020247035351A patent/KR20240161689A/ko active Pending
- 2023-03-27 JP JP2024556786A patent/JP2025512818A/ja active Pending
- 2023-03-27 MA MA69209A patent/MA69209B1/fr unknown
- 2023-03-27 CN CN202380037794.6A patent/CN119136785A/zh active Pending
-
2024
- 2024-09-24 CO CONC2024/0012879A patent/CO2024012879A2/es unknown
- 2024-09-24 MX MX2024011703A patent/MX2024011703A/es unknown
- 2024-10-24 ZA ZA2024/08058A patent/ZA202408058B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499038A1 (en) | 2025-02-05 |
| PL4499038T3 (pl) | 2026-04-27 |
| JP2025512818A (ja) | 2025-04-22 |
| IL315699A (en) | 2024-11-01 |
| EP4499038B1 (en) | 2025-12-03 |
| CN119136785A (zh) | 2024-12-13 |
| MX2024011703A (es) | 2024-11-08 |
| AU2023241243A1 (en) | 2024-11-07 |
| CA3250835A1 (en) | 2023-09-28 |
| KR20240161689A (ko) | 2024-11-12 |
| ZA202408058B (en) | 2026-01-28 |
| EP4499038C0 (en) | 2025-12-03 |
| HRP20260166T1 (hr) | 2026-03-27 |
| WO2023180575A1 (en) | 2023-09-28 |
| US20250228781A1 (en) | 2025-07-17 |
| ES3062067T3 (en) | 2026-04-08 |
| CO2024012879A2 (es) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025138849A (ja) | プリナブリン組成物及びその使用 | |
| Ohtake et al. | In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats | |
| CA2641880C (en) | Treatment of duchenne muscular dystrophy | |
| AU706279B2 (en) | Use of serotonin antagonists (5HT3) for treating fibro myalgia | |
| CN1305470C (zh) | 制备细自乳化的药物组合物的方法 | |
| EP0533280B2 (en) | Novel medical use for tachykinin antagonists | |
| AU702106B2 (en) | Use of carbazole compounds for the treatment of congestive heart failure | |
| US5225407A (en) | 5-HT3 receptor antagonists for the treatment of autism | |
| US8906951B1 (en) | Use of NK-1 receptor antagonists in pruritus | |
| AU688739B2 (en) | Method and composition for the treatment of Parkinson's disease | |
| AU2005249231A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| AU735381B2 (en) | New use | |
| KR20110118830A (ko) | Ｎｋ 수용체 길항제의 용도 | |
| ZA202408058B (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| WO2008113747A1 (en) | Medicaments useful as potassium channel modulators | |
| AU2002350832B2 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
| JP3598116B2 (ja) | 遅発性ジスキネジアの治療用医薬組成物とその利用 | |
| EP3025711B1 (en) | Medicine for preventing or treating hypertension | |
| JPS597119A (ja) | 鎮痛剤組成物 | |
| CA1110170A (en) | Antihypertensive compositions | |
| Nenoff et al. | In vitro susceptibility testing of Malassezia furfur against rilopirox | |
| CA1200499A (en) | Synergistic compositions of nalbuphine and non- narcotic analgesic compounds | |
| JP2007091661A (ja) | 外用抗真菌剤組成物 | |
| WO1999055340A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT EN ASSOCIATION UN ANTAGONISTE V1a DE L'ARGININE-VASOPRESSINE ET UN ANTAGONISTE DES RECEPTEURS AT1 DE L'ANGIOTENSINE II | |
| WO1998034922A1 (en) | Prophylactic or therapeutic agent for diabetic complication |